Kornimate/medical-research-clean huggingface dataset:
musculoskeletal health of the upper extremity in emerging health professionals

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome is the most expensive upper extremity work-related musculoskeletal disorder, impacting 10 million people annually and costing employers up to $113,695 per incident. there is currently no established method to detect this disorder prior to the onset of symptoms and nerve damage. preliminary research suggests that sonography-a relatively inexpensive, widely available, increasingly portable technology-can provide a non-invasive and pain-free method of early detection that could reduce incidence, improve targeted interventions and ultimately reduce costs. the primary aims of this study are to establish predictive validity of a novel method for early detection using sonographic imaging and to identify task components of intensive functional hand activity associated with morphologic changes.

this longitudinal study will follow dental hygiene students-a high-risk population with minimal retrospective and controlled prospective task exposure-for two years and compare them to a non-exposed cohort of occupational therapy students to investigate the primary aims. this research is directed at the national occupational research agenda's (nora) healthcare and social assistance sector with a focus on the national institute of occupational safety and health's (niosh) exposure assessment and musculoskeletal disorders cross-sectors. intermediate outcomes of this research will establish sonographic imaging as an early detection tool for workplace-screening and inform methods for combining measures of nerve morphology, neurophysiology, and subjective symptoms for predicting the development of work-related carpal tunnel syndrome. this work will also inform the development of targeted preventive interventions for task components of intensive hand activities that are related to changes in tissue morphology. identifying morphologic changes in early-stages of pathology and the specific task components linked to these changes are the first steps toward early detection and prevention of work-related carpal tunnel syndrome.

Eligibility criteria:
inclusion criteria: * enrollment in one of the academic programs (i.e., register and pay for classes) exclusion criteria: * \<18 years of age * prior carpal tunnel release surgery * prior diagnosis of median nerve pathology or other poly-neuropathy that includes the median nerve

Keywords: ultrasonography nerve conduction velocity ergonomics work related injury cumulative trauma disorders
efficacy and safety of an'ningpai expectorant in non-cf bronchiectasis

Conditions: Bronchiectasis Adult

Summary: the objective of this study was to assess whether the long-term use of oral an'ningpai enteric soft capsuleson (300 mg, three times daily, 12 months) might reduce the incidence of exacerbations and improve the quality of life in patients with non-cf bronchiectasis.

mucus hypersecretion plays an essential role in bronchiectasis. it has been deduced that reducing the production of mucus or improving the clearance of sputum in the airway is the key to break down this "vicious cycle" and enhance the therapeutic efficacy for bronchiectasis. the investgators aimed to assess whether the long-term use of oral an'ningpai enteric soft capsules (300 mg, three times daily) might reduce the rate of exacerbations and improve the quality of life in patients with bronchiectasis.

Eligibility criteria:
inclusion criteria: 1) subjects older than 18 ; 2)a diagnosis of bronchiectasis was according to the 2010 british thoracic society guidelines; 3) with hypersecretion ：high viscous sputum symptoms (sputum traits score 2-3 points) ;4) patients had least two exacerbations in the past year and were in a state for at least 4 weeks prior to randomization exclusion criteria: 1) cystic fibrosis or other etiologies (such as immunodeficiency, allergic bronchopulmonary aspergillosis, traction bronchiectasis caused by emphysema, advanced pulmonary fibrosis, etc.); 2)primary diagnosis of copd or asthma; 3)a history of severe cardiovascular disease; 4)comorbidity with liver disease, kidney disease, malignant tumor, gastric ulcer, or intestinal malabsorption; 5)a known allergy to eucalyptol , limonene and pinene enteric soft capsules; 6)pregnancy or lactation (for women);7)a history of prior macrolide use of more than 1 week; 8)and poor compliance

Keywords: brochiectasis adult hypersecretion exacerbation
first-line treatment for es-sclc with chemotherapy combined with pd-1/pd-l1 inhibitor sequential thoracic radiotherapy

Conditions: Extensive-stage Small-cell Lung Cancer

Summary: this is an open-label, single arm phase ii study designed to observe and evaluate the efficacy and safety of sequential thoracic radiotherapy in the first-line treatment of extensive small cell lung cancer with chemotherapy combined with approved pd-1/pd-l1 inhibitors.

this study a single arm prospective phase ii study. all the enrolled patients will be patients with es-sclc who did not have pd after 4-6 cycle of platinum-based chemotherapy in combination with an pd-1/pd-l1 inhibitors. then, those enrolled patients would be treated with thoracic radiotherapy concurrently with pd-1/pd-l1 maintenance therapy.

Eligibility criteria:
inclusion criteria: 1. age between18 years and 75 years. 2. histologic or cytologic confirmation of extensive-stage small cell lung cancer. 3. initially treated patients with extensive sclc showed no disease progression after 4-6 cycles of chemotherapy combined with pd-1/pd-l1 inhibitors. 4. presence of at least one measurable lesion (according to recist v1.1). 5. ecog performance status of 0 or 1. 6. life expectancy of at least 3 months. 7. adequate bone marrow, liver and kidney function. 8. adequate pulmonary function with fev1 \>1 l or \>30 % of predicted value and dlco \>30 % of predicted value exclusion criteria: 1. previous t cell co-stimulation or immune checkpoint therapy. 2. previous received chemoradiotherapy for limited-stage sclc. 3. central nervous system metastasis with clinical symptoms. 4. multiple liver metastases (patients with isolated liver metastases, metastatic lesions \< 3cm could be included). 5. patients with spinal cord compression. 6. idiopathic pulmonary fibrosis, institutional pneumonia, drug-induced pneumonia or idiopathic pneumonia, or evidence of active pneumonia during screening (patients with active pulmonary tuberculosis couldn't be enrolled). 7. have received any other investigational drug treatment or participated in another interventional clinical study within 4 weeks prior to signing the informed consent. 8. in the 5 years prior to the study, subjects had prior or concurrent malignancies requiring active treatment. 9. subjects with any severe and/or uncontrolled disease (hypertension, heart disease, infection, cirrhosis, active hepatitis, aids, third space effusion). 10. known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. 11. severe allergic reactions to any of the monoclonal antibodies are known to occur.
declic patient education program : assessment through a population health intervention research approach (le declic epri)

Conditions: Cancer Patients With Cancer Pain

Summary: cancer pain is a frequent symptom, reported by 20 to 70% of patients in any stage of the cancer disease : 60 to 70% in the advanced stage of the disease and 20 to 40% among the survivors. among patients who report pain, 40% report undertreated pain. strengthening pain management in cancer is a specific objective of the french cancer plan. providing patient education for cancer pain management is recommended since small to moderate efficacy of patient education on pain intensity and interference was found in all meta-analysis. an effect size comparable with some analgesic agents. however, recommendations suggest improvement in order to increase effectiveness and population reach of those interventions. the declic epri intervention aim at addressing all the issues raised by patient education for cancer pain management. it was developed according to the framework of michie's behavior change wheel theory.


Eligibility criteria:
inclusion criteria: 1. patient aged over 18. 2. followed in the participant comprehensive cancer center. 3. all cancer types, location and stage. 4. patient under any anticancer treatment (including hormonal therapy) or patient has stopped his treatment (including hormonal therapy) maximum 2 years before inclusion. 5. patient experiencing cancer pain and/or his treatments for 3 months or more. 6. all previous and concomitant treatments are accepted. 7. participation to another clinical trial is accepted. 8. patient has accepted to participate to the study and signed informed consent form or his legal representative. 9. patient affiliated to the social security healthcare. exclusion criteria: 1. cognitive impairment preventing to understand the patient education program. 2. language barrier preventing to understand the patient education program. 3. physical impairment preventing patient to attend to the patient education program.
qpi-1002 phase 3 for prevention of major adverse kidney events (make) in subjects at high risk for aki following cardiac surgery

Conditions: Cardiac Surgery

Summary: this trial is designed to evaluate qpi-1002 versus placebo for the prevention of major adverse kidney events (make) in subjects at high risk for acute kidney injury following cardiac surgery. half of the participants will receive qpi-1002 while the other half will receive placebo.

this is a randomized, double-blind, placebo-controlled, phase 3 trial to evaluate qpi-1002 versus placebo for the prevention of major adverse kidney events in subjects at high risk for acute kidney injury following cardiac surgery. subjects will be dosed with active drug or placebo after the completion of cardiovascular surgery.

Eligibility criteria:
key inclusion criteria: * male or female, age ≥ 18 years old * at risk for aki following cardiac surgery on the basis of at least one of the following pre-operatively assessed risk factors: * reduced renal function * diabetes with ongoing insulin treatment * albuminuria * undergoes non-emergent open chest cavity cardiovascular surgeries, with use of cardiopulmonary bypass (cpb), with or without hypothermic circulatory arrest key exclusion criteria: * emergent surgeries, including aortic dissection, and major congenital heart defects * undergoes cardiac surgery off cpb for subjects ≥45 years old. (cardiac surgery off cpb for subjects \<45 years old is allowed.) * perioperative or post cardiac surgery, an left ventricular assist device (lvad) is inserted or anticipated

Keywords: make aki
a study of oral palbociclib (pd-0332991), a cyclin-dependent kinase inhibitor, in patients with advanced cancer

Conditions: Neoplasms; Lymphoma, Non-Hodgkin

Summary: pd-0332991 may work in cancer by stopping cancer cells from multiplying. pd-0332991 is in a new class of drugs called cyclin-dependent kinase (cdk inhibitors). this research study is the first time that pd-0332991 will be given to people. pd-0332991 is taken by mouth daily.


Eligibility criteria:
inclusion criteria: * advanced solid tumors (excluding sclc and retinoblastoma) or follicular of diffuse large cell non-hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition; tumors must express rb * adequate blood cell counts, kidney function and liver function and and ecog score of 0, 1, or 2. * patients may have to have tumor biopsy before and after treatment. exclusion criteria: * prior stem cell or bone marrow transplant * uncontrolled infection, unstable or sever intercurrent medical condition, or current drug or alcohol abuse * active or unstable cardiac disease or history of heart attack within 6 months

Keywords: advanced cancer
1,5-ag as a marker of postprandial hyperglycemia and glucose variability in well-controlled type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: the aim of this study was to evaluate the correlation between 1,5-anhydroglucitol in patients with hba1c \<7%, and glycemic excursions as assessed by the continuous glucose monitoring system compared to fructosamine.

1,5-anhydroglucitol (ag) is a glucose analogue present in the plasma of healthy subjects. physiologically, the plasma levels of 1,5-ag are very stable and only a small quantity is excreted in the urine. it is competitively reabsorbed with glucose in the renal tubules. therefore, in the hyperglycemic state where glycosuria is present, glucose competitively inhibits renal tubular reabsorption of 1,5-ag and consequently the plasma 1,5-ag levels decrease. when glycemia is normalized and glycosuria is resolved, 1,5-ag levels increase. the usefulness of 1, 5-ag in reflecting glycemic excursions have been demonstrated in moderately controlled patients to some extent, although some studies reveal controversial results. therefore, the aim of this study was to evaluate the association of 1,5-ag and postprandial hyperglycemia determined using the continuous glucose monitoring system (cgms) in dm patients with hba1c\<7% and evaluate the usefulness of 1,5-ag as a marker of glycemic control compared to hba1c and fructosamine.

Eligibility criteria:
inclusion criteria: * hba1c \< 7% * hba1c modification \<0.5% in the previous 3 months * no recent addition of oral hypoglycemic medications or change in insulin dose \>10% previous 3 months exclusion criteria: * pregnancy * anemia (hb \<10.0 g/dl) * liver disease (alt \>2 unl) * hypoalbuminemia (albumin \<3.5 g/dl) * serum creatinine \>2 mg/dl * acute or chronic renal tubulointerstitial disease * severe medical illness

Keywords: 1,5-anhydroglucitol
assessment of poliovirus type 2 immunogenicity of one and two dose schedule with ipv and fipv when administered at 9-13 months of age in bangladesh

Conditions: Poliomyelitis

Summary: following a recommendation on october 2017 meeting of the strategic advisory group of experts (sage) on immunization; low- risk bopv-using countries may adopt 2 dose fipv schedule prior to global opv cessation as it provides better seroconversion than 1 full dose ipv and in the post-cessation era, the 2 fipv doses will provide sufficient (above 90%) seroconversion. countries, which delayed the introduction of ipv or had a vaccine stock-out, should provide 1 full dose or 2 fipv doses to all children who were missed as soon as supply becomes available. the ipv supply situation is expected to improve in 2018; all countries are expected to have access to ipv for their routine immunization programmes from the end of the first quarter of 2018. while immunogenicity after one and two doses of ipv and fipv has been estimated when administered to younger children ; the immunogenicity of ipv (or fipv) when administered at 9 months of age or later is not known. we propose to conduct a study to assess the immunogenicity of one and two doses of fipv and ipv when administered between 9-13 months of age.


Eligibility criteria:
inclusion criteria: 1. apparently healthy children with no obvious clinical symptom of illness 2. parents/legal guardians of participants willing to give written informed consent and willing to comply with study protocol. 3. free of obvious health problems (congenital abnormalities, severe malnutrition, acute or chronic diarrhea, bleeding disorder etc) as established by medical history and screening evaluation including clinical examination. 4. resident of study area. exclusion criteria: 1. participation in another clinical trial in the 4 weeks preceding the (first) trial vaccination or planned participation in another clinical trial during the present trial period. 2. a diagnosis or suspicion of congenital or acquired immunodeficiency disorder, malignancy, 3. a diagnosis or suspicion of bleeding disorder 4. acute or persistent diarrhoea 5. history of allergy or systemic hypersensitivity to any of the vaccine components 6. chronic illness at a stage that could interfere with trial conduct or completion. 7. presence of significant malnutrition 8. history of any neurological disorder or history of seizure (febrile or afebrile), or encephalopathy, encephalitis, hypotonic-hyporesponsive episode. 09. febrile illness or acute illness on the day of inclusion -
effect of intraoperative neuromuscular blockade on postoperative sore throat and hoarseness

Conditions: Sore Throat

Summary: investigators assess and compare postoperative sore throat and hoarseness in the group using the muscle relaxant and not using it during the operation.

the muscle relaxant is usually used during the operation to maintain moderate relaxation but, it can't be used in the surgery to need eletrophysiological monitoring during the operation. in this sturdy, the investigators assess the postoperative sore throat and hoarseness and compare the effect of muscle relaxant in the group using the muscle relaxant and not using it in terms of the incidence and severity of postoperative sore throat and hoarseness.

Eligibility criteria:
inclusion criteria * patients scheduled to undergo elective lumbar spinal surgery exclusion criteria * known or predicted difficult airway * neuromuscular diseases * hepatic or renal dysfunction * diseases or anatomical abnormalities in the neck, larynx, or pharynx * requirement for postoperative mechanical ventilation

Keywords: muscle relaxant
qt dispersion in patients with systemic lupus erythematosus (sle)

Conditions: SLE

Summary: qt dispersion can be a useful, simple noninvasive method for the early detection of cardiac involvement in sle patients with active disease. the investigators therefore recommend cardiovascular evaluation for every sle patient with an sledai higher than 10.

objective: patients with systemic lupus erythematosus (sle) have increased cardiovascular morbidity and mortality. although autopsy studies have documented that the heart is affected in most sle patients, clinical manifestations occur in less than 10%. qt dispersion is a new parameter that can be used to assess homogeneity of cardiac repolarization and autonomic function. we compared the increase in qt dispersion in sle patients with high disease activity and mild or moderate disease activity. methods: one hundred twenty-four patients with sle were enrolled in the study. complete history and physical exam, ecg, echocardiography, exercise test and sle disease activity index (sledai) were recorded. twenty patients were excluded on the basis of our exclusion criteria. the patients were divided to two groups based on sledai: 54 in the high-score group (sledai \>10) and 50 in the low-score group (sledai \<10).

Eligibility criteria:
inclusion criteria: * no administration of drugs that would potentially influence qt duration except hydroxychloroquine * no history of ischemic heart disease, congestive heart failure, atrial fibrillation, bundle branch block or abnormal serum electrolytes * normal resting ecg and a good-quality ecg recording to measure the qt interval. exclusion criteria: * moderate or severe valve disease * atrial fibrillation and other ecg abnormalities * systolic left ventricular dysfunction (ejection fraction \ 5.5 mm * unreliable identification of the end of the t wave in the ecg and * known presence of cardiac disease including hypertension, diabetes or coronary artery disease.

Keywords: sle disease activity score qt dispersion
exploring two treatments for misophonia

Conditions: Misophonia

Summary: while the investigators continue to work on better understanding misophonia, it is also important to identify treatments that can help people who are currently suffering. further, it is important that the treatments provided are acceptable to the people who receive them. in this study, participants will complete one of two treatments the investigators believe can help manage symptoms of misophonia: the unified protocol or process-based therapy. both treatments will use evidence-based psychological principles (e.g., managing attention or behavior) in a flexible manner and will focus on developing skills to help reduce the distress and impairment associated with misophonia. the aims of this study are (1) to explore the acceptability and feasibility of these treatments for individuals who experience misophonia and (2) to examine whether these treatments help reduce symptoms associated with misophonia.


Eligibility criteria:
inclusion criteria: * over age 18 * able to read english * meet criteria for interfering symptoms of misophonia * live in north carolina exclusion criteria: * under age 18 * current mania * current psychotic disorder * current anorexia * presents with a condition that requires immediate prioritization in treatment (e.g., suicide planning or intent) * has received any treatment specifically for misophonia in the past year
total neoadjuvant therapy versus standard therapy of locally advanced rectal cancer with high risk factors for failure

Conditions: Rectal Cancer

Summary: in a retrospective study, the investigators will compare patients with locally advanced rectal cancer with high risk factors for failure who were treated with standard therapy or with total neoadjuvant therapy.


Eligibility criteria:
inclusion criteria: * histologically proven locally advanced rectal cancer and * the presence of one of the factors: t4, n2, positive mesorectal fascia, presence of extramural vascular invasion or presence of lateral lymph node. exclusion criteria: * distant metastases, * concomitant malignancy, * inflammatory bowel disease, or * malabsorption syndrome.